Denosumab
- Generic Name
- Denosumab
- Brand Names
- Prolia, Xgeva, Wyost, Jubbonti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 615258-40-7
- Unique Ingredient Identifier
- 4EQZ6YO2HI
- Background
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and...
- Indication
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be use...
- Associated Conditions
- Bone Fractures, Bone Giant Cell Tumor, Bone Loss, Bone pain, Spinal Cord Compression, Bone destruction, High risk of fracture Osteoporosis, Refractory Hypercalcemia of malignancy
- Associated Therapies
- -
Denosumab Effect on Bone Quality and Function After Lumbar Fusion Surgery
- Conditions
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT05415657
- Locations
- 🇨🇳
ShenzhenPH, Shenzhen, Guangdong, China
A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 301
- Registration Number
- NCT05402865
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳West China Hospital of Sichuan University, Beijing, Beijing, China
Multicenter Study in Postmenopausal Women with Osteoporosis, ALVOBOND
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 532
- Registration Number
- NCT05395091
- Locations
- 🇬🇪
Investigational Site 9903, Tbilisi, Georgia
🇬🇪Investigational Site 9905, Tbilisi, Georgia
🇵🇱Investigational Site 4810, Zamość, Poland
Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05278338
- Locations
- 🇨🇳
The Second Hospital of Jilin University, Changchun, Jilin, China
FITMI - First In Treating Male Infertility
- Conditions
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Martin Blomberg Jensen
- Target Recruit Count
- 180
- Registration Number
- NCT05212337
- Locations
- 🇩🇰
Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark
Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 122
- Registration Number
- NCT05106517
- Locations
- 🇨🇳
ShenzhenPH, Shenzhen, Guangdong, China
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT05101018
- Locations
- 🇺🇸
Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
🇺🇸James J. Peters VA Medical Center, Bronx, New York, United States
The Optimal Long Term Treatment Strategy of Anti-resorptive Medications---The Extension of Denosumab Sequential Therapy
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05091086
- Locations
- 🇨🇳
National Taiwan University Hospital, Yunlin branch, Douliu, Yunlin County, Taiwan
Anabolic Therapy in Postmenopausal Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05010590
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 300
- Registration Number
- NCT04711109
- Locations
- 🇺🇸
Mountain Blue Cancer Care Center - Swedish, Englewood, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers - Swedish, Englewood, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.